Design, synthesis, and evaluation of mitomycin-tethered phosphorothioate oligodeoxynucleotides

Bioconjugate Chemistry

Volumn 7, Issue 6, 1996, Pages 659-669

  Huh, Nam ^a   Rege, Ajay A ^b   Yoo, Byungwoo ^a   Kogan, Timothy P ^b   Kohn, Harold ^a  

^a University of Houston   (United States)

^b TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; AMINO ACIDS; DNA SEQUENCES; SULFUR COMPOUNDS;

ALKYLATING AGENTS; BUFFERED SOLUTIONS; DESIGN EVALUATION; DESIGN SYNTHESIS; DINUCLEOTIDES; DNA BONDING; GUANINE; MITOMYCIN; MITOMYCIN C; TRINUCLEOTIDES;

DICHLOROMETHANE;

EID: 0030293114     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc960060n     Document Type: Article

References (71)

1. Milligan, J. F., Matteucci, M. D., and Martin, J. C. (1993) Current concepts in antisense drug design. J. Med. Chem. 36, 1923-1937.
2. Kiely, J. S. (1994) Recent advances in antisense technology. Annu. Rep. Med. Chem. 29, 297-306.
3. Lown, J. W. (1992) Lexitropsins: rational design of DNA sequence reading agents as novel anti-cancer agents and potential cellular probes. Anticancer Drug. Des. 3, 25-40.
4. Nielsen, P. E. (1991) Sequence-selective DNA recognition by synthetic ligands. Bioconjugate Chem. 2, 1-12.
5. Bailly, C., Colson, P., Houssier, C., Houssin, R., Mrani, D., Gosselin, G., Imbach, J.-L., Waring, M. J., Lown, J. W., and Henichart, J.-P. (1992) Binding properties and DNA sequence-specific recognition of two bithiazole-linked netrospin hybrid molecules. Biochemistry 31, 8349-8362.
6. McConnaughie, A. W., and Jenkins, T. C. (1995) Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity. J Med. Chem. 38, 3488-3501.
7. Wyatt, M. D., Lee, M., Garbiras, B. J., Souhami, R. L., and Hartley, J. A. (1995) Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. Biochemistry 34, 13034-13041.
8. Dervan, P. B. (1986) Design of sequence-specific DNA-binding molecules. Science 232, 464-471 and references cited therein.
9. Sluka, J. P., Bruist, M., Horvath, S. J., Simon, M. I., and Dervan, P. B. (1987) Synthesis of a sequence-specific DNA-cleaving peptide. Science 238, 1129-1132.
10. Steitz, T. A. (1990) Structural studies of protein-nucleic acid interaction: the sources of sequence-specific binding. Q. Rev. Biophys. 23, 205-280.
11. Harrison, S. C., and Aggarwal, A. K. (1990) DNA recognition by proteins with the helix-turn-helix motif. Annu. Rev. Biochem. 59, 933-969.
12. Praseuth, D., Perrouault, L., Le Doan, T., Chassignol, M., Thuong, N. T., Lhomme, J., and Helene, C. (1988) Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation. Proc. Natl. Acad. Sci. U.S.A. 85, 1349-1353.
13. Cooney, M., Czernuszewicz, G., Postel, E. H., Flint, S. J., and Hogan, M. E. (1988) Site-specific oligonucleotide binding represses transcription of human c-myc gene in vitro. Science 241, 456-459.
14. Bergstrom, D. E., and Gerry, N. P. (1994) Precision sequence-specific cleavage of a nucleic acid by a minor-groove-directed metal-binding ligand linked through N-2 of deoxyguanosine. J. Am. Chem. Soc. 116, 12067-12068.
15. Povsic, T. J., Strobel, S. A., and Dervan, P. B. (1992) Sequence-specific double-strand alkylation and cleavage of DNA mediated by triple-helix formation. J. Am. Chem. Soc. 114, 5934-5941.
16. Carter, S. K., and Crooke, S. T. (1979) Mitomycin C. Current Status and New Developments, Academic Press, New York.
17. Iyer, V. N., and Szybalski, W. (1964) Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science 745, 55-58.
18. Moore, H. W., and Czerniak, R. (1981) Naturally occurring quinones as potential bioreductive alkylating agents. Med. Res. Rev. 1, 249-280.
19. Tomasz, M. (1994) The mitomycins: Natural cross-linkers of DNA. Molecular Aspects of Anticancer Drug-DNA Interactions (S. Neidle and M. Waring, Eds.) Vol. 2, pp 312-348, Macmillan, Boca Raton, FL.
20. Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G. L., and Nakanishi, K. (1987) Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235, 1204-1208.
21. Li, V.-S., and Kohn, H. (1991) Studies on the bonding specificity for mitomycin-DNA monoalkylation processes. J. Am. Chem. Soc. 113, 275-283.
22. Kumar, S., Lipman, R., and Tomasz, M. (1992) Recognition of specific DNA sequences by mitomycin C for alkylation. Biochemistry 31, 1399-1407.
23. Kohn, H., Li, V.-S., and Tang, M.-s. (1992) Recognition of mitomycin C-DNA monoadducts by UVRABC nuclease. J. Am. Chem. Soc. 114, 5501-5509.
24. Kohn, H., Li, V.-S., Schiltz, P., and Tang, M.-s. (1992) On the origins of the DNA sequence selectivity of mitomycin monoalkylation transformations. J. Am. Chem. Soc. 114, 9218-9220.
25. De Mesmaeker, A., Häner, R., Martin, P., and Moser, H. E. (1995) Antisense oligonucleotides. Acc. Chem. Res. 28, 366-374.
26. Agrawal, S. (1992) Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 10, 152-158.
27. Mercola, D., and Cohen, J. S. (1995) Antisense approaches to cancer gene therapy. Cancer Gene Ther. 2, 47-59.
28. Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R., and Rosenberg, R. D. (1992) Antisense c-myb oligonucleotides inhibit initial arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
29. Pickering, G., Weir, L., Jekanowski, J., and Isner, J. M. (1992) Inhibition of proliferation of human vascular smooth muscle cells using antisense oligonucleotides to PCNA. J. Am. Coll. Cardiol. 19, 165A.
30. Spier, E., and Epstein, S. E. (1992) Inhibition of smooth muscle cell proliferation by an antisense oligonucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation 86, 538-547.
31. Simons, M., and Rosenberg, R. D. (1992) Antisense non-muscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. 70, 835-843.
32. Biro, S., Fu, Y. M., Yu, Z. X., and Epstein, S. E. (1993) Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc. Natl. Acad. Sci. U.S.A. 90, 654-658.
33. Shi, Y., Hutchinson, H. G., Hall, D. J., and Zalewski, A. (1993) Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 88, 1190-1195.
34. Limbach, P. A., Grain, P. F., and McCloskey, J. A. (1995) Molecular mass measurement of intact ribonucleic acids via electrospray ionization quadrupole mass spectrometry. J. Am. Soc. Mass Spectrom. 6, 27-39.
35. Choi, D., Yoo, B., Colson, K. L., Martin, G. E., and Kohn, H. (1995) C(10) Halogen 10-des(carbamoyloxy)porfiromycins: synthesis, chemistry, and biological activity. J. Org. Chem. 60, 3391-3396.
36. Kinoshita, S., Uzu, K., Nakano, K., and Takahashi, T. (1971) Mitomycin derivatives. 2. Derivatives of decarbamoylmitosane and decarbamoylmitosene. J. Med. Chem. 14, 109-112.
37. Han, I., Russell, D. J., and Kohn, H. (1992) Studies on the mechanism of mitomycin C(1) electrophilic transformations: structure-reactivity relationships. J. Org. Chem. 57, 1799-1807.
38. Urakawa, C., Tsuchiya, H., Nakano, K.-I., and Nakamura, N. (1981) Preparation and biological activities of 10-decarbamoyloxy-9-dehydromitomycin B and its analogs. J. Antibiot. 34, 1152-1156.
39. Kono, M., Kasai, M., and Shirahata, K. (1990) The derivation of 1a-demethylmitomycin G from mitomycin C. J. Antibiot. 43, 383-390.
40. Kasai, M., and Kono, M. (1992) Studies on the chemistry of mitomycins. Syn. Lett. 778-790 and references therein.
41. The anticipated ∈-values for 23 at 260 nm and 360 (365) nm in the UV-visible spectrum can be predicted, see: Borowy-Borowski, H., Lipman, R., Chowdary, D., and Tomasz, M. (1990) Duplex oligodeoxyribonucleotides cross-linked by mitomycin C at a single site: Synthesis, properties, and cross-link reversibility. Biochemistry 29, 2992-2999.
42. Webb, J. S., Cosulich, D. B., Mowat, J. H., Patrick, J. B., Broschard, R. W., Meyer, W. E., Williams, R. P., Wolf, C. F., Fulmor, W., Pidacks, C., and Lancaster, J. E. (1962) The structures of mitomycins A, B and C and porfiromycin-Part I. J. Am. Chem. Soc. 84, 3185-3187.
43. Kan, M., Shi, E.-G., and McKeehan, W. (1991) Identification and assay of fibroblast growth factor receptors. Methods Enzymol. 198, 158-171.
44. Iyengar, B. S., Sami, S. M., Remers, W. A., Bradner, W. T., and Schurig, J. E. (1983) Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7. J. Med. Chem. 26, 16-20.
45. Iyengar, B. S., Sami, S. M., Tarnow, S. E., Remers, W. A., Bradner, W. T., and Schurig, J. E. (1983) Mitomycin C analogues with secondary amines at position 7. J. Med. Chem. 26, 1453-1457.
46. Kono, M., Saitoh, Y., Kasai, M., Shirahata, K., Morimoto, M., and Ashizawa, T. (1993) Synthesis and structure-activity relationships of new dimeric mitomycin derivatives; 7-N,7′-N′-bis(omega-thioalkyl)dimitomycins. J. Antibiot. 46, 1428-1438.
47. Sawhney, K., and Kohn, H. (1989) Mitomycin C analogues with a substituted hydrazine at position 7. Synthesis, spectral properties, and biological activity. J. Med. Chem. 32, 248-252.
48. Fishbein, P. L., and Kohn, H. (1987) Synthesis and antineoplastic activity of (N)-1a-formyl and (N)-1a-thionoformyl derivatives of mitomycin C and (N)-2-methylaziridine. J. Med. Chem. 30, 1767-1773.
49. De Marre, A., Soyez, H., Schacht, E., Shoaibi, M. A., Seymour, L. W., and Rihova, B. (1995) Synthesis and evaluation of macromolecular prodrugs of mitomycin C. J. Controlled Release 36, 87-97.
50. De Marre, A., Soyez, H., and Schacht, E. (1994) Synthesis of macromolecular mitomycin C derivatives. J. Controlled Release 32, 129-137.
51. For oligodeoxynucleotide attachment at the C(7) position in mitomycin C, see: Maruenda, H., and Tomasz, M. (1995) Mitomycin C-conjugated oligonucleotides: interaction with DNA and RNA. FASEB J. 9, A966.
52. Milligan, J. F., Matteucci, M. D., and Martin, J. C. (1993) Current concepts in antisense drug design. J. Med. Chem. 36, 1923-1937.
53. Varma, R. S. (1993) Synthesis of oligonucleotide analogues with modified backbones. Syn. Lett. 621-637.
54. Saltis, J., Thomas, A. C., Agrotis, A., Campbell, J. H., Campbell, G. R., and Bobik, A. (1995) Expression of growth factor receptors in arterial smooth muscle cells. Dependency on cell phenotype and serum factors. Atherosclerosis 118, 77-87.
55. Xin, X., Johnson, A. D., Scott-Burden, T., Engler, D., and Cascells, W. (1994) The predominant form of fibroblast growth factor receptor expressed by proliferation human arterial smooth muscle cells in culture is type I. Biochem. Biophys. Res. Commun. 204, 557-564.
56. Brothers, T. E., Robison, G., Elliot, B. M., Boggs, J. M., Frankel, A. E., and Willingham, M. C. (1995) Upregulation of bFGF receptor expression after carotid bypass. J. Surg. Res. 58, 28-32.
57. Lindner, V., and Reidy, M. A. (1993) Expression of bFGF and its receptor by SMC and endothelium in injured rat arteries: An en face study. Circ. Res. 73, 589-595.
58. Becker, D., Lee, P. L., Rodeck, U., and Herlyn, M. (1992) Inhibition of the FGFR1 gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogens 7, 2303-2313.
59. Kato, J., Wanebo, H., Calabresi, P., and Clark, J. W. (1992) bFGF production and growth factor receptors as potential targets for melanoma therapy. Melanoma Res. 2, 13-23.
60. Mima, T., Ueno, H., Fischman, D. A., Williams, L. T., and Mikawa, T. (1995) FGFR1 is required for in vivo cardiac myocyte proliferation at early embryonic stages of heart development. Proc. Natl. Acad. Sci. U.S.A. 92, 467-477.
61. Danishefsky, S., and Ciufolini, M. (1984) Leucomitomycins. J. Am. Chem. Soc. 106, 6424-6425.
62. Kohn, H., Zein, N., Lin, X. Q., Ding, J.-Q., and Kadish, K. M. (1987) Mechanistic studies on the mode of reaction of mitomycin C under catalytic and electrochemical reductive conditions. J. Am. Chem. Soc. 109, 1833-1840.
63. Beck, T. W., Huleihel, M., Gunnell, M., Bonner, T. I., and Rapp, U. R. (1987) The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res. 15, 595-609.
64. Avalos, M., Babiano, R., Cintas, P., Jimenez, J. L., Palacios, J. C., and Valencia, C. (1994) Condensation of 2-amino-2-deoxysugars with isothiocyanates. Synthesis of cis-1,2-fused glycopyrano heterocycles. Tetrahedron 50, 3273-3296.
65. Dionne, C. A., Crumley, G. R., Bellot, F., Kaplow, J. M., Searfoss, G., Ruta, M., Burgess, W. H., Jaye, M., and Schlessinger, J. (1990) Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J. 9, 2685-2692.
66. Chatterijee, M., and Rokita, S. E. (1994) The role of a quinone methide in the sequence specific alkylation of DNA. J. Am. Chem. Soc. 116, 1690-1697.
67. Li, T., Zeng, Q., and Rokita, S. E. (1994) Target-promoted alkylation of DNA. Bioconjugate Chem. 5, 497-500.
68. Burgess, T. L., Fisher, E. F., Ross, S. L., Bready, J. V., Qian, Y.-X., Bayewitch, L. A., Cohen, A. M., Herrera, C. J., Hu, S. S.-F., Kramer, T. B., Lott, F. D., Martin, F. H., Pierce, G. F., Simonet, L., and Farrell, C. L. (1995) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. U.S.A. 92, 4051-4055.
69. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., and Stein, C. A. (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627.
70. Bennett, C. F., Chiang, M. Y., Wilson-Lingardo, L., and Wyatt, J. R. (1994) Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides. Nucleic Acids Res. 22, 3202-3209.
71. Stein, C. A., and Krieg, A. M. (1994) Editorial: Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4, 67-69.